Gli inibitori del recettore IIb/IIIa - Cuorediverona.it
Gli inibitori del recettore IIb/IIIa - Cuorediverona.it Gli inibitori del recettore IIb/IIIa - Cuorediverona.it
% of Patients IIb/IIIa Inhibition with or without PCI Experience with Abciximab in Patients with ACS Death or MI through 30 Days Invasive Strategy 25 20 15 10 5 0 83% ↓ 47% ↓ 63% ↓ 73% ↓ p = 0.001 p = 0.003 p = 0.001 10.9 1.8 9.0 4.8 10.4 p = 0.001 14.1 3.7 3.9 Medical Rx p = NS EPIC CAPTURE EPILOG EPISTENT GUSTO IV Placebo Abciximab ACS EHJ 1999; 1 (Suppl. E):E27-E35 Lancet 2001; 357 : 1915-24 8.0 8.6
IV GP IIb/IIIa Inhibitors in ACS: Death or MI at 30 Days (N=31.402 – no elective PCI), Study Placebo IV Gp IIb/IIIa Odds Ratio 95% CI PRISM 7.1% 5.8%* 0.80 0.60-1.06 PRISM-PLUS PLUS 12.0% (*) 8.7% 0.70 0.50-0.98 0.98 ( † ) 13.6%* 1.17 0.80-1.70 PARAGON-A 11.7% (l) 10.3% 0.87 0.58-1.29 (h) 12.3% 1.06 0.72-1.55 PURSUIT 15.7% (l) 13.4% 0.83 0.70-0.99 0.99 (h) 14.2% 0.89 0.79-1.00 PARAGON-B 11.4% 10.6% 0.92 0.77-1.09 GUSTO-IV 8.0% (24h) 8.2% 1.02 0.83-1.24 (48h) 9.1% 1.15 0.94-1.39 Overall 11.8% 10.8% t 0.91 0.85-0.98 0.98 0 1.0 2.0 Gp IIb/IIIa Better * Without heparin. † With/without heparin. (l), Low dose; (h), High-dose. Boersma E, et al. Lancet. 2002;359:189-198. Placebo Better P=.015
- Page 1 and 2: P come piastrine, come prezzemolo
- Page 3 and 4: Formazione del trombo nelle ACS sen
- Page 5 and 6: GP IIb-IIIa Inhibitors costituiscon
- Page 8 and 9: Cardiologia “De Gasperis”- Nigu
- Page 10 and 11: Inibitori GPIIb/IIIa Artist’s con
- Page 12: Characteristics of GP IIb/IIIa Inhi
- Page 15 and 16: Patogenesi delle Sindromi Coronaric
- Page 17 and 18: Sindromi Coronariche Acute ST-segme
- Page 19: 8 16 Lancet 1997; 349:1429-35 35
- Page 22 and 23: UA/NSTEMI Beneficio solo se PCI
- Page 26 and 27: GP IIb/IIIa Inhibitor During Medica
- Page 28 and 29: Peterson E.D.et al.: Early use of g
- Page 30 and 31: ISAR-COOL study - Pre-procedural ou
- Page 32 and 33: CAPTURE Results by Troponin T Statu
- Page 34 and 35: GP IIb/IIIa Inhibition in Diabetics
- Page 36 and 37: Gli inibitori GP IIb/IIIa IIIa ridu
- Page 38 and 39: ESC PCI guidelines 2004 2004 Recomm
- Page 40 and 41: SCA: UA/NSTEMI L’applicazione del
- Page 42 and 43: Coronarografia in base a età e TIM
- Page 44 and 45: Sindromi Coronariche Acute ST-segme
- Page 46 and 47: Occlusive thrombus contains Fibrin
- Page 48 and 49: Abciximab Improves ST Res-90 min ST
- Page 50 and 51: RAPPORT, ISAR 2, ADMIRAL, CADILLAC
- Page 52 and 53: 5 GPIIb/IIIa inhibitors trials in P
- Page 54 and 55: BMS and abciximab display a synergi
- Page 56 and 57: Study design Inclusion Criteria: ST
- Page 58 and 59: Multi-STRATEGY MULTIcenter evaluati
- Page 60 and 61: GUSTO V AMI GUSTO V - Trial Schemat
- Page 62 and 63: IIb/IIIa Varie...ed eventuali
- Page 64 and 65: IIb/IIIa e PCI: Nei pazienti stabil
- Page 66: Conclusioni Glycoprotein IIb/IIIa I
IV GP <strong>IIb</strong>/<strong>IIIa</strong> Inhib<strong>it</strong>ors in ACS: Death or MI at 30<br />
Days (N=31.402 – no elective PCI),<br />
Study<br />
Placebo IV Gp <strong>IIb</strong>/<strong>IIIa</strong> Odds Ratio 95% CI<br />
PRISM 7.1% 5.8%* 0.80 0.60-1.06<br />
PRISM-PLUS<br />
PLUS 12.0% (*) 8.7% 0.70 0.50-0.98<br />
0.98<br />
( † ) 13.6%* 1.17 0.80-1.70<br />
PARAGON-A 11.7% (l) 10.3% 0.87 0.58-1.29<br />
(h) 12.3% 1.06 0.72-1.55<br />
PURSUIT 15.7% (l) 13.4% 0.83 0.70-0.99<br />
0.99<br />
(h) 14.2% 0.89 0.79-1.00<br />
PARAGON-B 11.4% 10.6% 0.92 0.77-1.09<br />
GUSTO-IV<br />
8.0% (24h) 8.2% 1.02 0.83-1.24<br />
(48h) 9.1% 1.15 0.94-1.39<br />
Overall 11.8% 10.8% t 0.91 0.85-0.98<br />
0.98<br />
0 1.0 2.0<br />
Gp <strong>IIb</strong>/<strong>IIIa</strong> Better<br />
* W<strong>it</strong>hout heparin. † W<strong>it</strong>h/w<strong>it</strong>hout heparin. (l), Low dose; (h), High-dose.<br />
Boersma E, et al. Lancet. 2002;359:189-198.<br />
Placebo Better<br />
P=.015
Change language